Nicole Roth
Overview
Explore the profile of Nicole Roth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
224
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiang Q, Lok J, Roth N, Andersen S, Perls T, Song Z, et al.
medRxiv
. 2025 Jan;
PMID: 39802799
Background: Recent studies have revealed a strong association between the e2 allele of the Apolipoprotein E ( gene and lipid metabolites. In addition, carriers appear to be protected from cognitive...
2.
Fricke C, Ulrich L, Kochmann J, Gergen J, Kovacikova K, Roth N, et al.
Mol Ther Nucleic Acids
. 2024 Nov;
35(4):102360.
PMID: 39524696
Coronavirus disease 2019 (COVID-19) mRNA vaccines that have contributed to controlling the SARS-CoV-2 pandemic induce specific serum antibodies, which correlate with protection. However, the neutralizing capacity of antibodies for emerging...
3.
Scaria P, Roth N, Schwendt K, Muratova O, Alani N, Lambert L, et al.
NPJ Vaccines
. 2024 Jan;
9(1):9.
PMID: 38184666
Malaria transmission-blocking vaccines (TBV) are designed to inhibit the sexual stage development of the parasite in the mosquito host and can play a significant role in achieving the goal of...
4.
Medina-Magues L, Muhe J, Jasny E, Medina-Magues E, Roth N, Lopera-Madrid J, et al.
NPJ Vaccines
. 2023 Mar;
8(1):31.
PMID: 36871059
Despite the success of the widely used attenuated yellow fever (YF) vaccine, its global supply remains a substantial barrier to implementing vaccination campaigns in endemic regions and combating emerging epidemics....
5.
Roth N, Gergen J, Kovacikova K, Mueller S, Ulrich L, Schon J, et al.
Vaccines (Basel)
. 2023 Feb;
11(2).
PMID: 36851196
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron and its subvariants (BA.2, BA.4, BA.5) represented the most commonly circulating variants of concern (VOC) in the coronavirus disease 2019 (COVID-19) pandemic in...
6.
Corleis B, Hoffmann D, Rauch S, Fricke C, Roth N, Gergen J, et al.
Nat Commun
. 2023 Feb;
14(1):816.
PMID: 36781853
Combining optimized spike (S) protein-encoding mRNA vaccines to target multiple SARS-CoV-2 variants could improve control of the COVID-19 pandemic. We compare monovalent and bivalent mRNA vaccines encoding B.1.351 (Beta) and/or...
7.
Roth N, Schon J, Hoffmann D, Thran M, Thess A, Mueller S, et al.
Vaccines (Basel)
. 2022 Aug;
10(8).
PMID: 36016139
More than two years after the emergence of SARS-CoV-2, 33 COVID-19 vaccines, based on different platforms, have been approved in 197 countries. Novel variants that are less efficiently neutralised by...
8.
Gebre M, Rauch S, Roth N, Gergen J, Yu J, Liu X, et al.
NPJ Vaccines
. 2022 Aug;
7(1):88.
PMID: 35915094
mRNA vaccines can be developed and produced quickly, making them prime candidates for immediate outbreak responses. Furthermore, clinical trials have demonstrated rapid protection following mRNA vaccination. Thus, we sought to...
9.
Gebre M, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado N, et al.
Nature
. 2021 Nov;
601(7893):410-414.
PMID: 34794169
The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in humans. CV2CoV is a second-generation mRNA vaccine containing...
10.
Gebre M, Rauch S, Roth N, Gergen J, Yu J, Liu X, et al.
bioRxiv
. 2021 Nov;
PMID: 34751269
Importance: mRNA vaccines can be developed and produced in record time. Here we demonstrate induction of rapid antibody responses by mRNA vaccines encoding two different viral antigens by day 5...